Clinical Trials Logo

Clinical Trial Summary

Vifor International Inc. is seeking real-world evidence (RWE) to better understand the epidemiology, patient characteristics, and management of CKD-aP in the real-world clinical setting.


Clinical Trial Description

This is a non-interventional, cross-sectional, multicentre, and multinational (European) study. The non-interventional study (NIS) design allows the observation of patients in large haemodialysis (HD) centres reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by the sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour. The CENSUS-EU represents a cross-sectional study design of a representative selection of patients undergoing HD at 113 large dialysis centres across 7 countries in Europe. Prot. v.2.0, 9 May 2023 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05524467
Study type Observational
Source Vifor Pharma
Contact
Status Active, not recruiting
Phase
Start date February 2, 2023
Completion date June 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03532568 - Klotho in Chronic Kidney Disease-associated Pruritis (CKD-aP) N/A
Withdrawn NCT05625542 - Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
Not yet recruiting NCT06466421 - Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis Phase 4
Completed NCT05482698 - The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial Phase 2